MedTrace Logo

Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults

NCT04265105 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-03-31

No results posted yet for this study

Summary

Investigators will test the superiority of Superiority Trial of Fluticasone-Vilanterol as needed in mild asthma compared to standard of care

Conditions

Interventions

DRUG

fluticasone-vilanterol

LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid

DRUG

Standard Preparation

inhaled SABA or Inhaled corticosteroid

Sponsors & Collaborators

  • Royal College of Surgeons in Ireland - Medical University of Bahrain

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2023-01-18
Completion
2023-01-18

Countries

  • Bahrain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04265105 on ClinicalTrials.gov